학술논문

Fertility care for all: impact of New York State's Medicaid expansion on infertility care.
Document Type
Article
Source
Journal of Assisted Reproduction & Genetics. Feb2024, Vol. 41 Issue 2, p423-428. 6p.
Subject
*INDUCED ovulation
*INFERTILITY
*FERTILITY
*HUMAN fertility
*MEDICAID
*FERTILITY clinics
Language
ISSN
1058-0468
Abstract
Purpose: To assess whether the New York State (NYS) mandate expanding Medicaid coverage of fertility diagnostic testing and treatment is successfully increasing patient access to and utilization of fertility care. Methods: A retrospective chart review was performed of NYS Medicaid patients who presented for fertility services to a large academic reproductive endocrinology and infertility (REI) clinic. Information on patient demographics, medical history, diagnostic testing, treatments, and outcomes was collected. Patients presenting to the clinic in the 1 year prior to the mandate (October 1, 2018–September 30, 2019) were compared to patients presenting in the 1 year after the mandate (October 1, 2019–September 30, 2020). Primary outcomes of the study were differences in presentation to the clinic between the two cohorts and differences in utilization of infertility diagnostic testing and treatment. Secondary outcomes were differences in treatment outcomes. Results: A significantly larger percentage of Medicaid patients presented to the clinic for fertility assessment post-mandate (22%) as compared to pre-mandate (9%, p < 0.05). There were no demographic differences between the pre- and post-mandate patient groups. A similar percentage of patients completed diagnostic testing pre- vs. post-mandate. Post-mandate patients underwent more treatment cycles with ovulation induction medications compared to natural treatment cycles. There was no significant difference in pregnancy rates pre- vs. post-mandate. Conclusion: The NYS Medicaid mandate allowed a significantly larger percentage of Medicaid patients to present for fertility evaluation. The patients in the post-mandate cohort underwent more treatment cycles with ovulation induction medications compared to natural cycles. [ABSTRACT FROM AUTHOR]